BIOLOGICAL MODELING

Our vast tumor organoid repository enables new possibilities for therapy selection and drug discovery

We aim to transform therapy selection and drug discovery and development by building the world’s largest library of human ex vivo tumor-derived organoids* that are characterized by molecular features and associated clinical outcomes in robust, reproducible 3D models.

Our Solutions

Custom organoid screening models

Client-selected organoids screened with or without allogeneic MHC-matched PBMCs, tailored to your research needs. A variety of compound classes can be screened ranging from small molecules to biologics, viral vectors, cell engagers, and cellular therapies.

Tumor Origin: Pan-Cancer, client-selected indications
Molecular Profiling: Client-selected molecular alterations, mutations, CNVs, fusions, etc.

Predefined organoid screening models

Predefined models for routine screening in organoids containing actionable alterations across cancer types. Compounds can be screened alone and in combinations, providing a rapid and cost-effective alternative to in vivo preclinical animal experiments.

PanTumor 60™: primary and metastatic tumors
- Tumor Origin: Breast, Head & Neck, NSCLC-AC, NSCLC-SQ, Endometrial, Gastroesophageal, Pancreatic, Colorectal, Ovarian, Liver
- Molecular Profiling: Tempus xT molecular profiles and whole transcriptome
PanTumor IO™: primary and metastatic tumors with allogeneic MHC-matched PBMCs
- Tumor Origin: Breast, Head & Neck, NSCLC-AC, NSCLC-SQ, Endometrial, Gastroesophageal, Pancreatic, Colorectal, Ovarian, Liver
- Molecular Profiling: Tempus xT molecular profiles and whole transcriptome, four digit HLA genotyping
- Designed to screen cell engagers and adoptive cell therapeutics

Single cell RNA sequencing

Characterize cell populations of interest with precision–identify and validate complex signatures and identify biomarkers of therapeutic response

Spatial transcriptomics

Uncover spatio-temporal patterns of gene expression in two dimensions to better characterize the relationships between molecular profiles and therapeutic response

Bespoke Solutions

A large Biopharma collaborator used Tempus’ patient-derived organoids to unlock a critical investment decision. Read More

PAN-CANCER TUMOR ORGANOIDS

Breast
Colon
Endometrial Adeno
Gastric
Head + Neck SCC
Liver HCC
NSCLC Adeno
NSCLC SCC
Ovarian
Pancreatic

Our solutions can be broadly applied to preclinical and post-approval strategies

Target validation
Indication selection
Phenotypic (clinical) + Exploratory (MOA) studies
Exploration of rare patient mutations and alterations
Combination identification
Signature development for responder enrichment
Immune cell activation
Label expansion plans

Our Differentiators

500+

commercially available biological models
Full characterization

of tumor organoids with Tempus xT solid tumor comprehensive profiling
Flexible

3D confocal imaging assays with AI analytics on every tumor organoid drug sensitivity screen
Innovative pipeline

of automation-driven assays enable expedited experimental processes
CAP-accredited, CLIA-certified

laboratories

How it works

Individual human ex vivo tumor-derived organoids* are screened in Tempus’ high-throughput environment. Tempus organoids are NGS-qualified and have been pre-screened against a panel of chemotherapies and small molecule therapeutics. Our 3D models serve as the basis for drug screening efforts for drug discovery and development.

Organoids are grown in proprietary chemically defined conditions from core biopsies or surgical resections.
Organoid histology is verified by board-certified medical pathologists.
Full transcriptomic profiles are generated by RNA sequencing.
Tumor mutation recapitulation is assessed by overlap of somatic variants between tumor and tumor organoids via the Tempus xT 648 gene panel.
Organoids are phenotyped via high content assays, which are then analyzed via automated machine vision algorithms employing state-of-the-art computer vision models to segment organoids, quantify infiltrating immune cells, and predict drug efficacies along with other clinical endpoints as desired.

*Specimens collected under IRB-approved research protocols

A Pan-Cancer Organoid Platform for Precision Medicine
Larsen et al. optimize a pan-cancer platform with tumor organoids from over 1,000 patients and establish standards for culture conditions, molecular characterization, and therapeutic profiling using deep learning coupled with light microscopy.
READ PUBLICATION
Applying Machine Vision to Empower Preclinical Development of Cell Engager and Adoptive Cell Therapeutics in Patient-Derived Organoid Models of Solid Tumors
Khare et al. demonstrate the scalability and throughput of a machine vision tumor organoid immune co-culture platform across multiple unique patient-derived tumor organoid lines bearing a target of interest, enabling future discovery of biomarkers of therapeutic response and resistance.
READ PUBLICATION
A Platform of CDK4/6 Inhibitor-Resistant Patient-Derived Breast Cancer Organoids Illuminates Mechanisms of Resistance and Therapeutic Vulnerabilities
Hanker et al. show that patient-derived organoids established from ER+ MBC biopsies represent valuable models to understand and explore diverse mechanisms of CDK4/6i resistance.
READ PUBLICATION

Partnering with Tempus is investing in the future

We’ve created a biological modeling infrastructure centered on ex vivo tumor organoids to help you accelerate your research needs.